43 results about "Head neck cancer" patented technology

Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These compositions can be used therapeutically to treat persons or animals who have cancer, e.g., head and neck cancer, breast cancer or prostate cancer.

Stable monomeric phosphaplatins, namely, (pyrophosphato)platinum(II) or platinum(IV) complexes containing a cis-cyclohexanediamine ligand or enantiomerically enriched or enantiopure trans-cyclohexanediamine ligands, and synthesis of these complexes, are provided. Efficacies and toxicities of the phosphaplatin compounds are determined toward a variety of cancers, including sensitive and resistant ovarian cancers, head and neck, and colon cancers. Compositions comprising the platinum complexes, and methods for treatment of proliferative diseases or disorders by means of the complexes or the compositions comprising them are disclosed.

The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC.

The invention provides an HNC (Head and Neck Cancer) prognosis biomarker based on a lymph node microbial flora and application of the HNC prognosis biomarker, and belongs to the technical field of disease prognosis and molecular biology. According to the invention, the 16S ribosomal RNA gene of the lymph node microbial flora of an HNC patient is subjected to high-throughput sequencing, so that it is proved that different species exist in flora species of metastatic lymph nodes and non-metastatic lymph nodes in the HNC patient; furthermore, through a microbial flora symbiotic relationship network, it is found that the flora interrelation between the species of the metastatic lymph node and the species of the non-metastatic lymph node of the HNC patient is also different at the genus level; the result discovers the characteristics of the microbiome of the metastatic lymph node and the non-metastatic lymph node of the HNC patient for the first time; and meanwhile, it is known by analysis that the flora difference characteristics (diversity index values and relative abundance of different species) have a good prediction effect on the lifetime (total lifetime and three-year lifetime) of the HNC patient, so that the invention has a good practical application value.

The present invention provides a pharmaceutical composition containing recombinant hemoglobin protein or tetramer or dimer or subunit for tissue oxygenation and treating cancer. The recombinant hemoglobin protein or tetramer or dimer or subunit-based therapeutic agent is also effective for treating cancer. The recombinant hemoglobin or tetramer or dimer or its subunit moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The recombinant hemoglobin or tetramer or dimer or its subunit-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent, radiotherapeutic agent, anti-cancer protein drug to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence.

The invention provides a tumor targeted molecule capable of specifically binding to a plurality of tumors, i.e., ferritin, and a contrast agent for diagnosis of tumor or a therapeutic drug containing the tumor targeted molecule. The contrast agent or the therapeutic drug has the characteristics of no or low toxicity, strong specificity, a small utilization amount, high stability in vivo, etc, and is especially applicable to targeted diagnosis or treatment of malignant tumor tissue, e.g., liver cancer tumor, melanin tumor, lung cancer tumor, breast cancer tumor, colonic / rectal cancer tumor, pancreas cancer tumor, stomach cancer tumor, ovarian cancer, head and neck cancer, neuroglioma, etc.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention provides antibodies, which can be used as a therapeutic agent for treating and / or preventing diseases associated with cells expressing CLD18, including tumor-related diseases, such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck, and gallbladder cancers.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent / therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and / or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and / or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The present invention provides antibodies that can be used as therapeutic agents for the treatment and / or prevention of diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, Liver, head and neck and gallbladder cancers.

Provided is a method of diagnosing head and neck cancer by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using normal individual- and subject-derived samples, wherein the risk of head and neck cancer can be diagnosed through metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample, and thus a risk group of head and neck cancer can be diagnosed early and predicted, thereby delaying the onset of head and neck cancer or preventing the onset of head and neck cancer through appropriate management, and even after head and neck cancer occur, early diagnosis for head and neck cancer can be implemented, thereby lowering the incidence of head and neck cancer and increasing therapeutic effects.

The present invention relates to HPV-positive as well as HPV-negative screening platforms that are highly serum-dependent, for use as HNSCC models. These HNSCC models die reproducibly in serum-deprived conditions and the introduction of driver mutations (or increased levels of the WT gene) confers enhanced cell survival and proliferation under serum deprivation. These platforms have the major advantages of allowing functional screening of mutations in relevant HNSCC models (HPV-positive and HPV-negative). In addition to oncogene screening, this model can also be used in drug discovery. Specifically, cells expressing mutations that confer increased survival can then be screened against panels of therapeutic agents to determine if the mutation(s) can predict the optimal treatment for patients whose tumors harbor the mutation(s).

The invention discloses a novel molecular marker and its application in preparation of a kit for the diagnosis and prognosis of head and neck cancer. The RNA sequences of the novel molecular marker are shown in SEQ ID NO:1-SEQ ID NO:48. Based on the marker of the invention, a mathematical model for the diagnosis of head and neck cancer is constructed; the model has high sensitivity, good specificity, AUC up to 0.981, and good diagnostic effect. In addition, these 48 tRF fragments can also be used as molecular markers for head and neck cancer classification and prediction of patient survival; in the test data, according to the expression of tRFs, head and neck cancer tumor samples were clustered into 4 subtypes, and analyzed by survival curves It shows that there are significant differences in the survival periods of these subtypes; the novel tRF molecular marker disclosed in the present invention has the characteristics of good diagnostic indicators, can be effectively used in the diagnosis, classification and prognosis of head and neck cancer, and has high clinical application and promotion value.

The invention discloses a preparation of carboryl celecoxib and its application in boron neutron capture therapy drugs for head and neck cancer, and relates to the fields of medicinal chemistry and radiation medicine. The compound can be prepared by stepwise substitution and addition reaction of celecoxib with 3-bromopropyne and decaborane in toluene solution. The invention has simple preparation process, easy operation, high product yield and high purity. The compound of the present invention has been proved by head and neck cancer cell experiment results that the compound has high selectivity to head and neck cancer cells, and has obvious apoptosis-inducing effect on head and neck cancer cells in boron neutron capture therapy. Compared with the existing clinical drugs used in boron neutron capture therapy, the compound not only has high boron loading capacity and strong tumor selectivity, but also can exert anti-inflammatory effect while exerting the curative effect of radiotherapy, and reduce the toxic and side effects of treatment.

The invention relates to an epidermal growth factor receptor monoclonal antibody and a hybridoma cell line secreting the monoclonal antibody. The monoclonal antibody can be used for application in a kit for detection of cancer cells, wherein the cancer cells preferably comprise epidermis tumor, head and neck cancer, breast cancer, renal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer and colon cancer; and the monoclonal antibody is used for treatment of related diseases.